|
|
| A High Through-Put Test Interrogating 442 Small Non-Coding RNAs (sncRNA) Extracted From Urine Exosomes Accurately Identifies and Stratifies Prostate Cancer Into Low, Intermediate, or High-Risk Disease |
| Laurence Klotz, MD, FRCSC
|
| Laurence Klotz discusses the results of the Sentinel® Prostate Cancer Platform, a test for stratification of prostate cancer risk groups. The miR Sentinel® PCC4 Test is a non-invasive molecular test based on the analysis of small non-coding RNAs isolated from non-DRE urinary exosomes. This test provided high sensitivity for the presence or absence of any cancer, low risk versus intermediate or high-risk disease, and intermediate versus high risk disease.
|
|
|
|
|
|
| Prospective Study of 68Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging
|
| Andrei Iagaru, MD, FACNM
|
| The American Urological Association (AUA) annual meeting included a late-breaking abstract session with a presentation by Dr. Andrei Iagaru discussing the prospective study of 68Ga-RM2 PET/MRI in biochemically recurrent prostate cancer and negative conventional imaging.
|
|
|
|
|
|
| Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: Analysis of 18F-DCFPyL Uptake in Possible Extra-Pelvic Oligometastases
|
| Andrei Iagaru, MD, FACNM
|
| The American Urological Association (AUA) annual meeting included a late-breaking abstract session with a presentation by Dr. Andrei Iagaru discussing the prospective evaluation of 18F-DCFPyL PET/CT in biochemically recurrent prostate cancer and the detection of extra-pelvic oligometastases. 18F-DCFPyl has been shown to have intense uptake in the bladder, kidneys, salivary glands, and lacrimal glands, with weak uptake in the liver, spleen, and bowel.
|
|
|
|
|
|
|
|
|
|
|
| A Phase II Randomized Clinical Trial Of Yoga In Men With Prostate Cancer
|
| Dharam Kaushik, MD
|
| In this study by Dharam Kaushik, Dr. Kaushik explores the impact of yoga on men with newly diagnosed prostate cancer before and after prostatectomy. It was found that yoga has important effects on quality of life (QoL), antitumor immune response, and inflammatory response. Based on the data, it can be concluded that perioperative yoga improved QoL, promoted an antitumor immune response, and attenuated inflammation in men undergoing prostatectomy. Yoga is feasible in this setting and has benefits that require further investigation.
|
|
|
|
|
|
| Masitinib Plus Docetaxel as First-Line Treatment of Metastatic Castrate Refractory Prostate Cancer: Results from Study AB12003
|
| Michel Pavic, MD
|
| Michel Pavic discusses the results of the AB12003 trial assessing masitinib plus docetaxel as first-line treatment of metastatic castration-resistant prostate cancer (mCRPC). Masitinib is an oral, small molecule drug that targets mast cell and macrophage activity. The combination of masitinib plus docetaxel may provide a new first-line treatment option for mCRPC patients with low metastatic involvement. |
|
|
|
|
|
| MRI-guided Focused Ultrasound (MRgFUS) Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results of a Phase IIb Multicenter Study
|
| Behfar Ehdaie, MD, MPH
|
| Behfar Ehdaie discusses the results of a phase IIb multicenter study assessing MRI-guided focused ultrasound focal therapy for intermediate-risk prostate cancer. These data support a randomized controlled trial in men with intermediate-risk prostate cancer seeking to avoid radical whole-gland treatment. |
|
|
|
|
|
| PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know |
| Steven Rowe, MD and Michael Gorin, MD |
| In this presentation by Drs. Michael Gorin and Steven Rowe, they provide a thorough, comprehensive overview of PSMA-targeted PET Imaging within the field of urology, with an emphasis on what Urologists need to know. While the focus is primarily on prostate cancer, they do briefly touch on the role of this novel technology for non-prostate malignancies. |
|
|
|
|
|
|
|
|
|
|
| Relationships of Sites and Burden of Metastases With Long-Term Outcomes and Molecular Subtypes in TITAN
|
| Anders Bjartell, MD
|
| In a moderated poster presentation at the American Urological Association Virtual Annual Meeting, the relationships between the number and location of metastases and signatures associated with poor prognosis and ADT insensitivity and outcome measures were assessed.
|
|
|
|
|
|
| Balancing Efficacy and Toxicity of Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer. Results from a Pooled Analysis of Three Prospective Randomized Trials |
| Giuseppe Cirulli, MD |
| Giuseppe Cirulli presents the results of their work examining risk stratification in this cohort. Dr. Cirulli concludes that, among patients with mCRPC, this model can help clinicians balancing the toxicity and efficacy of docetaxel. The three risk categories identified correlate with overall survival and may help inform shared decision-making. |
|
|
|
|
|
| Pembrolizumab Plus Olaparib in Patients With Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer (mCRPC): Updated Results From KEYNOTE-365 Cohort A With a Minimum of 11 Months of Follow-Up for All Patients |
| Luke T. Nordquist, MD |
| Luke Nordquist presents updated results from cohort A of the KEYNOTE-365 trial with a minimum of 11.4 months of follow-up. With this longer duration of follow-up, the combination of pembrolizumab and olaparib continued to show some antitumor activity in patients with molecularly unselected, docetaxel-pretreated mCRPC. |
|
|
|
|
|
| Comparison of the Cardiotoxicity of Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data |
| Alice Dragomir, MSc, Ph.D. |
| In a moderated poster presentation at the American Urological Association Annual Meeting, Alice Dragomir presented a real-world analysis of the comparative cardiovascular safety of abiraterone acetate and enzalutamide in patients with mCRPC. |
|
|
|
|
|
|
|
|
|
|
|
